Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Benitec Biopharma Inc. (BNTC)

0.2316   0.003 (1.31%) 06-09 13:33
Open: 0.225 Pre. Close: 0.2286
High: 0.239 Low: 0.220901
Volume: 68,695 Market Cap: 6(M)

Technical analysis

as of: 2023-06-09 1:43:41 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 0.31     One year: 0.36
Support: Support1: 0.18    Support2: 0.15
Resistance: Resistance1: 0.26    Resistance2: 0.31
Pivot: 0.22
Moving Average: MA(5): 0.22     MA(20): 0.22
MA(100): 0.23     MA(250): 0.39
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 30.8     %D(3): 29.7
RSI: RSI(14): 53
52-week: High: 2.09  Low: 0.13
Average Vol(K): 3-Month: 308 (K)  10-Days: 255 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BNTC ] has closed below upper band by 42.0%. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.23 - 0.23 0.23 - 0.24
Low: 0.22 - 0.22 0.22 - 0.22
Close: 0.23 - 0.23 0.23 - 0.23

Company Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Headline News

Thu, 18 May 2023
JMP Securities Analyst Reiterates Market Outperform Rating for ... - Best Stocks

Mon, 08 May 2023
Benitec Biopharma to Present at the JMP Securities Life Sciences ... - GlobeNewswire

Mon, 08 May 2023
Benitec Biopharma to Present at the OPMD International Conference - GlobeNewswire

Tue, 21 Feb 2023
7 Cheap Robinhood Stocks Under $1 To Watch Trading For Pennies - Penny Stocks

Mon, 13 Feb 2023
Benitec Biopharma Releases Second Quarter 2023 Financial ... - GlobeNewswire

Mon, 23 Jan 2023
Benitec Biopharma Enrolls First OPMD Subject into the Clinical ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 28 (M)
% Held by Insiders 2.442e+007 (%)
% Held by Institutions 7.9 (%)
Shares Short 189 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.915e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -28
Return on Assets (ttm) 336.7
Return on Equity (ttm) -131.8
Qtrly Rev. Growth 68000
Gross Profit (p.s.) 10.86
Sales Per Share -283.88
EBITDA (p.s.) 55652.2
Qtrly Earnings Growth -1.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -19 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 1.56

Stock Dividends

Dividend 0
Forward Dividend 317360
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.